Abstract: Provided are an experimental apparatus and method for regulating and controlling the Zeeman transition of magnetic resonance. The method includes: generating a constant background magnetic field by using a magnetic shielding cylinder, a background magnetic field coil, and a constant current source, and controlling a Larmor precession frequency corresponding to the background magnetic field to be equal to a frequency of a sinusoidal signal output by a radio frequency signal source; adjusting the amplitude of a signal output by a radio frequency signal source of a pump-probe atomic magnetometer to set a radio frequency signal to be a ?/2 pulse or a ? pulse; and then controlling the radio frequency signal source to output a series of sinusoidal radio frequency pulse strings having the same initial phase. The Zeeman transition of magnetic resonance is regulated and controlled by adjusting the time interval between the radio frequency pulse signals.

Abstract: The present invention relates to the technical field of organic compound synthesis, and particularly to a method for synthesizing silver (I) trifluoromethanethiolate. A method for synthesizing silver (I) trifluoromethanethiolate (CAS number: 811-68-7) is provided, which comprising synthesizing silver (I) trifluoromethanethiolate by using silver fluoride as a raw material, and using a trifluoromethanethiolate as a source providing trifluoromethylthio groups. In the present invention, the trifluoromethanethiolate is used as a source providing trifluoromethylthio groups, reacts with silver fluoride in a solvent to produce silver (I) trifluoromethanethiolate; and after separation and purification, a finished product of silver (I) trifluoromethanethiolate is obtained.

Abstract: The present invention belongs to the field of medical technology, and specifically relates to use of bromophenol-pyrazoline compounds for the treatment of feline coronavirus diseases. Studies carried out for the present invention revealed that bromophenol-pyrazoline compounds could inhibit activity of feline infectious peritonitis virus main protease (FIPV Mpro) and interfere with replication of feline infectious peritonitis virus (FIPV) in cells. In a clinical trial, the bromophenol-pyrazoline compounds can treat infectious peritonitis in cats naturally infected with the FIPV, greatly improve survival rate of cats, and can be used to prepare drugs for treating feline infectious peritonitis.

Abstract: The present invention relates to a compound, and in particular to a bromophenol-pyrazoline compound and a synthesis method and use thereof. The bromophenol-pyrazoline compound is represented by a general structural formula below: The bromophenol-pyrazoline compound provided in the present invention has efficient inhibitory activity against the main protease Mpro, and interferes with the replication of coronavirus in cells, indicating that the compound has the effect of treating coronavirus pneumonia and thus has a broad prospect of application in the preparation of drugs for treating coronavirus pneumonia.

Abstract: The invention belongs to the technical field of medicine, and particularly relates to use of bromophenol-pyrazoline compounds in the treatment of porcine coronavirus diseases. Through the research in the invention, it is found that the bromophenol-pyrazoline compounds inhibit replication of porcine coronaviruses at a cellular level, and can treat porcine coronavirus diseases (such as PEDV and TGEV) in clinical trials, greatly improving the survival rate of infected piglets, so the compounds can be used to prepare drugs for treating porcine coronavirus diseases.

Abstract: The present invention belongs to the field of medical technology, and specifically relates to use of bromophenol-pyrazoline compounds for the treatment of feline coronavirus diseases. Studies carried out for the present invention revealed that bromophenol-pyrazoline compounds could inhibit activity of feline infectious peritonitis virus main protease (FIPV Mpro) and interfere with replication of feline infectious peritonitis virus (FIPV) in cells. In a clinical trial, the bromophenol-pyrazoline compounds can treat infectious peritonitis in cats naturally infected with the FIPV, greatly improve survival rate of cats, and can be used to prepare drugs for treating feline infectious peritonitis.

Abstract: The invention belongs to the technical field of medicine, and particularly relates to use of bromophenol-pyrazoline compounds in the treatment of porcine coronavirus diseases. Through the research in the invention, it is found that the bromophenol-pyrazoline compounds inhibit replication of porcine coronaviruses at a cellular level, and can treat porcine coronavirus diseases (such as PEDV and TGEV) in clinical trials, greatly improving the survival rate of infected piglets, so the compounds can be used to prepare drugs for treating porcine coronavirus diseases.

Abstract: The present invention relates to a compound, and in particular to a bromophenol-pyrazoline compound and a synthesis method and use thereof. The bromophenol-pyrazoline compound is represented by a general structural formula below: The bromophenol-pyrazoline compound provided in the present invention has efficient inhibitory activity against the main protease Mpro, and interferes with the replication of coronavirus in cells, indicating that the compound has the effect of treating coronavirus pneumonia and thus has a broad prospect of application in the preparation of drugs for treating coronavirus pneumonia.

Abstract: The present invention relates to chemical total synthesis methods of six novel protein tyrosine phosphatase-1B (PTP1B) inhibitors and application of the inhibitors in the preparation of medicaments for treating type 2 diabetes mellitus (T2DM). The PTP1B inhibitors use one or more of the six compounds represented by the structural formulae 1, 2, 3, 4, 5 and 6, as active components. The compounds can enhance the sensitivity of an insulin receptor by inhibiting the activity of PTP1B, thereby having a favorable therapeutic effect on insulin-resistant T2DM.

Abstract: The present invention relates to chemical total synthesis methods of six novel protein tyrosine phosphatase-1B (PTP1B) inhibitors and application of the inhibitors in the preparation of medicaments for treating type 2 diabetes mellitus (T2DM). The PTP1B inhibitors use one or more of the six compounds represented by the structural formulae 1, 2, 3, 4, 5 and 6, as active components. The compounds can enhance the sensitivity of an insulin receptor by inhibiting the activity of PTP1B, thereby having a favorable therapeutic effect on insulin-resistant T2DM.